☆ 4.6 Editorial Material

GFR Decline as an End Point for Clinical Trials in CKD: A View From Europe

AMERICAN JOURNAL OF KIDNEY DISEASES (2014)

Journal

AMERICAN JOURNAL OF KIDNEY DISEASES

Volume 64, Issue 6, Pages 838-840

Publisher

W B SAUNDERS CO-ELSEVIER INC

DOI: 10.1053/j.ajkd.2014.10.001

Keywords

-

Categories

Urology & Nephrology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Urology & Nephrology

Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD

Hiddo J. L. A. Heerspink, Lesley Inker, Hocine H. Tighiouart, Willem Collier, Benjamin Haaland, Jiyu B. Luo, Gerald Appel, Tak Mao O. Chan, Raymond Estacio, Fernando Fervenza, Juergen Floege, Enyu H. Imai, Tazeen B. Jafar, Julia Lewis, Philip Kam-Tao Li, Francesco D. Locatelli, Bart Maes, Annalisa D. Perna, Ronald Perrone, Manuel P. Praga, Francesco Schena, Christoph Wanner, Di Xie, Tom Greene, CKD EPI CT

Summary: This study aims to develop a conceptual framework that combines albuminuria and GFR slope to better predict treatment effects on clinical endpoints in Phase 2 trials. The results demonstrate that combining the treatment effects on albuminuria and GFR slope improves the prediction of treatment effects on clinical endpoints. These findings may help inform the design of clinical trials for interventions aimed at slowing CKD progression.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Deficits in the Skeletal Muscle Transcriptome and Mitochondrial Coupling in Progressive Diabetes-Induced CKD Relate to Functional Decline

Daniel C. Bittel, Adam J. Bittel, Arun S. Varadhachary, Terri Pietka, David R. Sinacore

Summary: Two-thirds of individuals with type 2 diabetes will develop chronic kidney disease, leading to early frailty, mobility deficits, and increased mortality risk. The mechanisms linking renal decline to mobility deficits are crucial for identifying high-risk individuals and formulating effective treatment strategies. Skeletal muscle energetics and mitochondrial function play a key role in impairing physical function in the progression of T2DM-induced CKD.

DIABETES (2021)

Add to Collection

Article Urology & Nephrology

Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

Hiddo J. L. Heerspink, Niels Jongs, Brendon L. Neuen, Patrick Schloemer, Muthiah Vaduganathan, Lesley A. Inker, Robert A. Fletcher, David C. Wheeler, George Bakris, Tom Greene, Glenn M. Chertow, Vlado Perkovic

Summary: The effects of newer kidney protective agents on smaller declines in eGFR have been assessed and found to be comparable to the effects on kidney failure or death due to kidney failure. This suggests that composite endpoints incorporating smaller declines in eGFR can reduce the required number of participants in clinical trials without compromising statistical power.

KIDNEY INTERNATIONAL (2023)

Add to Collection

Article Transplantation

The effect of micro-particle curcumin on chronic kidney disease the MPAC-CKD randomized clinical trial

Matthew A. Weir, Michael Walsh, Meaghan S. Cuerden, Jessica M. Sontrop, Bradley L. Urquhart, Yong Jin Lim, Laura C. Chambers, Amit X. Garg

Summary: In this randomized, double-blind, placebo-controlled trial, it was found that micro-particle curcumin capsules (90 mg/day) did not slow the progression of albuminuric CKD over a period of 6 months.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Add to Collection

Review Allergy

A regulator's view on AIT clinical trials in the United States and Europe: Why successful studies fail to support licensure

Andreas Bonertz, Anubha Tripathi, Julia Zimmer, Christina Reeb, Susanne Kaul, Jennifer Bridgewater, Ronald L. Rabin, Jay E. Slater, Stefan Vieths

Summary: Clinical studies on allergen immunotherapy (AIT) show that its efficacy and safety depend on various factors. Obtaining licensure for AIT products requires consistent qualitative and quantitative composition throughout clinical development. Validating efficacy involves statistically significant differences and clinical relevance. Selection of meaningful inclusion and endpoint criteria is crucial. Data analysis should be based on the intention-to-treat population for objective assessment. Interpretations of clinical data in publications and regulatory reviews may differ due to their different objectives. Regulatory reviews consider the full data sets of all relevant clinical studies for informed decision-making on licensure.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Urology & Nephrology

The Number and Size of Individual Kidney Medullary Pyramids is Associated with Clinical Characteristics, Kidney Biopsy Findings, and CKD Outcomes among Kidney Donors

Adriana V. Gregory, Aleksandar Denic, Amr Moustafa, Praveen G. Dasaraju, Bhavya Poudyal, Joshua J. Augustine, Aidan F. Mullan, Panagiotis Korfiatis, Andrew D. Rule, Timothy L. Kline

Summary: The study investigates the clinical importance of the size and number of kidney lobes. It finds that the cortex and medullary volumes and pyramid counts reflect variations in nephron number and size and age-related nephrosclerosis.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Natalie Staplin, Richard Haynes, Kaitlin J. Mayne, Alistair J. Roddick, Brendon L. Neuen, Sibylle J. Hauske, Stefan D. Anker, Martina Brueckmann, Javed Butler, David Z. Cherney, Jennifer B. Green, Chih-Chin Liu, Finnian R. McCausland, Darren K. McGuire, John J. McMurray, Milton Packer, Vlado Perkovic, Marc S. Sabatine, Scott D. Solomon, Muthiah Vaduganathan, Christoph Wanner, Stephen D. Wiviott, Faiez Zannad, Hiddo J. L. Heerspink, Sarah Y. A. Ng, Doreen Zhu, Parminder Judge, David Preiss, Martin J. Landray, Colin Baigent, Jonathan R. Emberson, William G. Herrington, Deepak L. Bhatt, Bruce Neal, Silvio E. Inzucchi, Meg J. Jardine, Kenneth W. Mahaffey, David C. Wheeler

Summary: This study provides evidence that SGLT2 inhibitors can reduce the risk of kidney disease progression and acute kidney injury, not only in patients with type 2 diabetes at high cardiovascular risk, but also in patients with chronic kidney disease or heart failure regardless of diabetes status, primary kidney disease, or kidney function.

LANCET (2022)

Add to Collection

Editorial Material Urology & Nephrology

Shedding a light on sex disparity in clinical trials in CKD patients

Francesca Mallamaci, Giovanni Tripepi

Summary: Clinical studies often have an insufficient proportion of female participants, leading to a lack of sex-specific research data. This article highlights the gender imbalance in clinical studies, including those involving patients with chronic kidney disease. The absence of sex equity in research is a significant public health problem, as it hinders understanding of how drugs work differently in men and women. It is crucial to conduct further research on sex disparities in clinical studies to address the underrepresentation of women and promote gender equality in research.

CLINICAL KIDNEY JOURNAL (2023)

Add to Collection

Article Multidisciplinary Sciences

Association of serum total bilirubin levels with progressive renal decline and end-stage kidney disease: 10-year observational cohort study in Japanese patients with diabetes

Erina Eto, Yasutaka Maeda, Noriyuki Sonoda, Naoki Nakashima, Kunihisa Kobayashi, Ryoichi Takayanagi, Yoshihiro Ogawa, Toyoshi Inoguchi

Summary: This study found an association between serum total bilirubin levels and the progression of diabetic nephropathy and end-stage kidney disease. Patients with lower bilirubin levels were more likely to experience progressive renal decline and end-stage kidney disease. Serum total bilirubin levels may be useful in identifying high-risk patients for end-stage kidney disease.

PLOS ONE (2022)

Add to Collection

Editorial Material Oncology

Envisioning clinical trials as complex interventions

Kristian D. Stensland, Laura J. Damschroder, Anne E. Sales, Anne F. Schott, Ted A. Skolarus

Summary: Clinical trials are crucial for modern healthcare and have both societal and individual benefits. However, these trials often fail to achieve their goals and have low enrollment rates. The authors propose applying implementation science to clinical trials to improve their conduct and increase their effectiveness.

CANCER (2022)

Add to Collection

Editorial Material Clinical Neurology

Putting participants and study partners FIRST when clinical trials end early

Emily A. Largent, Sarah Walter, Nancy Childs, Penny A. Dacks, Shana Dodge, Hana Florian, Jonathan Jackson, Jorge J. Llibre Guerra, Erin Iturriaga, David S. Miller, Monica Moreno, Rachel L. Nosheny, Thomas O. Obisesan, Elena Portacolone, Bernadette Siddiqi, Nina Silverberg, Rueben C. Warren, Kathleen A. Welsh-Bohmer, Rebecca M. Edelmayer

Summary: Following the early termination of several clinical trials, there has been a call to improve communication and support for participants and their study partners. The Participant Follow-Up Improvement in Research Studies and Trials (Participant FIRST) Work Group was formed to identify best practices in addressing this issue. The work group proposed 17 key recommendations, including allocating sufficient resources, developing dyad-centered communication plans, assisting in building and maintaining support networks, and promptly informing dyads in the event of trial discontinuation.

ALZHEIMERS & DEMENTIA (2022)

Add to Collection

Article Immunology

Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials

Yang Xing, Feroza Yasinjan, Yajie Du, Huayue Geng, Ying Zhang, Minghua He, Rui Guo, Lei Yang, Jiayue Cui, Dongmei Mu, Ziling Liu, Hong Wang

Summary: Cervical cancer is a major global health issue, with limited treatment options for advanced cases. Immunotherapy has emerged as a promising approach for these patients and has shown significant progress in recent years.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Urology & Nephrology

End Point Considerations for Clinical Trials in Enteric Hyperoxaluria

Craig B. Langman, Dean Assimos, Melanie Blank, Juan Calle, Andreas Grauer, Annamaria Kausz, Dawn Milliner, Lama Nazzal, Kimberly Smith, Greg Tasian, Aliza Thompson, Kyle D. Wood, Elaine Worcester, Sixun Yang, Meaghan A. Malley, Felix Knauf, John C. Lieske

Summary: Enteric hyperoxaluria is a medical condition associated with increased urinary oxalate excretion, leading to kidney stone events and kidney failure. Currently, there are no approved therapies for this condition and it is unclear how to evaluate the efficacy of potential treatments. This study reviews potential clinical outcome measures and surrogate endpoints, but gaps in the data prevent definitive recommendations from being made.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Add to Collection

Article Immunology

Concordance of Early and Late End Points for Community-acquired Bacterial Pneumonia Trials

Stephen M. Bart, Sumathi Nambiar, Ramya Gopinath, Daniel Rubin, John J. Farley

Summary: In analyzing participant-level data from recent CABP trials submitted to the FDA, it was found that 85.6% of participants had concordant early and late end-point outcomes. Early end-point response was highly predictive of late end-point success, with certain factors like obesity, specific infections, prior antibacterial therapy, and baseline chest pain associated with discordance between early and late outcomes.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Hematology

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo, Jesse G. Dixon, Jennifer Le-Rademacher, Eva Hoster, Howard S. Hochster, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Catherine Sebban, Emmanuel Gyan, Kenneth Foon, Tina Nielsen, Umberto Vitolo, Gilles A. Salles, Qian Shi, Christopher R. Flowers

Summary: Observational studies and stand-alone trials have shown that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy have poor outcomes. This pooled analysis of clinical trials validates POD24 as a robust indicator of poor FL survival and identifies clinical predictors of early death and progression, which can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.

BLOOD (2022)

Add to Collection

Article Orthopedics

Osteochondral Repair and Electromechanical Evaluation of Custom 3D Scaffold Microstructured by Direct Laser Writing Lithography

Justinas Maciulaitis, Milda Miskiniene, Sima Rekstyte, Maksim Bratchikov, Adas Darinskas, Agne Simbelyte, Gintaras Daunoras, Aida Laurinaviciene, Arvydas Laurinavicius, Rimtautas Gudas, Mangirdas Malinauskas, Romaldas Maciulaitis

Summary: This study assessed a novel 3D microstructured scaffold seeded with allogeneic chondrocytes in a rabbit osteochondral defect model, demonstrating its efficacy and biocompatibility in both in vitro and in vivo experiments. The findings showed that the scaffold promoted cartilage repair in vivo, and cell addition enhanced cartilage formation.

CARTILAGE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics

Michiel J. Bakkum, Jelle Tichelaar, Paraskevi Papaioannidou, Robert Likic, Emilio J. Sanz Alvarez, Thierry Christiaens, Joao N. Costa, Romaldas Maciulaitis, Lorena Dima, Jamie Coleman, Milan C. Richir, Michiel A. van Agtmael

Summary: Improvement and harmonization of European clinical pharmacology and therapeutics (CPT) education is urgently needed. A survey of CPT teachers in European medical schools found that digital educational resources, including e-learning, simulators, virtual patients, and serious games, are widely used. However, the majority of these resources are not free or open, highlighting the need for more information on why teachers are not sharing their educational materials.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

EurOP2E - the European Open Platform for Prescribing Education, a consensus study among clinical pharmacology and therapeutics teachers

Michiel J. Bakkum, Milan C. Richir, Paraskevi Papaioannidou, Robert Likic, Emilio J. Sanz, Thierry Christiaens, Joao N. Costa, Romaldas Maciulaitis, Lorena Dima, Jamie Coleman, Jelle Tichelaar, Michiel A. van Agtmael

Summary: The study found that European CPT teachers perceived opportunities in using and creating open educational resources, but also faced challenges such as language barriers, local differences, lack of time, technological issues, difficulties with quality management, and copyright restrictions. Practical solutions discussed include a peer review system, clear indexing, and use of copyright licenses that permit adaptation of resources.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Infectious Diseases

The Glomerular Filtration Rate Estimators in the Pharmacokinetic Modelling in Acute Kidney Injury: An Observational Study

Silvijus Abramavicius, Vaidotas Galaune, Agile Tunaityte, Astra Vitkauskiene, Gintautas Gumbrevicius, Aurelija Radzeviciene, Romaldas Maciulaitis

Summary: The study found that current eGFR estimators for patients with acute kidney injury (AKI) pose risks of inaccuracy in renal function assessment and drug dosing, with the exception of the Cockcroft-Gault estimator, which is more appropriate.

ANTIBIOTICS-BASEL (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK

Sieta T. de Vries, Petra Denig, Adriana Andric, Marina Dimov Di Giusti, Alicia Ptaszynska-Neophytou, Linda Harmark, Peter G. M. Mol

Summary: The motives of HCPs and patients to report ADRs to national agencies were mostly similar across countries, providing guidance for promoting and increasing ADR reporting, while also highlighting areas for further refinement at a national level based on observed differences.

DRUG SAFETY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders

Carla J. Jonker, Sieta T. de Vries, H. Marijke van den Berg, Patricia McGettigan, Arno W. Hoes, Peter G. M. Mol

Summary: The study found that opinions on data and governance in rare disease registries are aligned across stakeholders, suggesting that they should not hinder collaboration. This supports efforts by the European Medicines Agency to encourage stakeholders to work with existing registries for regulatory decision making data collection.

DRUG SAFETY (2021)

Add to Collection

Editorial Material Cell & Tissue Engineering

Inclusivity and diversity: Integrating international perspectives on stem cell challenges and potential

Robin Fears, Hidenori Akutsu, Lara Theresa Alentajan-Aleta, Andres Caicedo, Antonio Carlos Campos de Carvalho, Miodrag Colic, Jillian Cornish, Giulio Cossu, Patrice Debre, Geoffrey Dierckxsens, Nagwa El-Badri, George Griffin, Patrick Chingo-Ho Hsieh, Maneesha S. Inamdar, Pradeep Kumar, Consuelo Macias Abraham, Romaldas Maciulaitis, Mamun Al Mahtab, Fergal J. O'Brien, Michael Sean Pepper, Volker ter Meulen

Summary: Regenerative medicine shows great potential, but concerns arise from unregulated therapies and premature regulatory approvals. The InterAcademy Partnership initiated a global effort to address opportunities and challenges in stem cell research, emphasizing the importance of supporting research, protecting patients, and fostering collaboration worldwide.

STEM CELL REPORTS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach

Esther de Vries, Elisabeth Bakker, Remy D. C. Francisca, Stijn Croonen, Petra Denig, Peter G. M. Mol

Summary: This study aimed to understand the procedures and practices in place for handling new drug safety information and DHPCs in Dutch hospitals. The results showed that drug safety information was considered in formulary decisions and treatment protocols, and DHPCs were primarily dealt with by individual professionals with very rare actions taken in response.

DRUG SAFETY (2022)

Add to Collection

Review Public, Environmental & Occupational Health

Attention for sex in COVID-19 trials: a review of regulatory dossiers

Sieta T. de Vries, Viktoriia Starokozhko, Ingrid M. M. Schellens, Leonoor Wijnans, Harald Enzmann, Marco Cavaleri, Peter G. M. Mol

Summary: This study evaluated sex proportionality and sex-specific efficacy and safety data in COVID-19 trials. It found under-representation of women in one treatment, but representative representation in other treatments. Currently, only a few products provide sex-specific efficacy and safety data, and it is important to make this information available for other products.

BMJ GLOBAL HEALTH (2022)

Add to Collection

Article Economics

How can a joint European health technology assessment provide an 'additional benefit' over the current standard of national assessments? Insights generated from a multi-stakeholder survey in hematology/oncology

Elaine Julian, Fabrizio Gianfrate, Oriol Sola-Morales, Peter Mol, Jean-Francois Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Joerg Ruof

Summary: This study conducted a multi-stakeholder survey to identify key areas where a joint European health technology assessment (HTA) could provide additional benefit compared to the existing independent national assessments. The findings highlight the need to address methodological and process challenges in order to achieve this.

HEALTH ECONOMICS REVIEW (2022)

Add to Collection

Article Pharmacology & Pharmacy

Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross-Sectional Analysis of Centralized Procedures in the European Union 2010-2020

Katerina M. Mantila, Anna M. G. Pasmooij, Christine Erikstrup Hallgreen, Peter G. M. Mol, Job F. M. van Boven

Summary: Medication adherence is a key factor affecting the efficacy and safety of medicines, but how it is addressed in European registration trials remains unknown. This study analyzed the marketing authorization dossiers of new medicines approved by the European Medicines Agency (EMA) between 2010 and 2020. The findings reveal significant variations in adherence measurement methods and definitions across different therapeutic areas and trials. Standardization of adherence definitions and measurement methods is necessary for a better understanding and comparison of medication efficacy.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making

Elisabeth Bakker, Kelly Plueschke, Carla J. Jonker, Xavier Kurz, Viktoriia Starokozhko, Peter G. M. Mol

Summary: Real-world data/evidence (RWD/RWE) can provide insightful information on medicines' clinical effects and guide regulatory decisions. However, further evaluation is needed to use RWD/RWE to demonstrate the efficacy of medicines. This study characterized RWD/RWE presented by applicants and analyzed its contribution to regulatory decisions on the benefit-risk profile of medicines. Common limitations of submitted RWD/RWE included missing data, lack of representativeness, and bias risks.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in Europe

Marko J. Kallio, Viktoriia Starokozhko, Eleonora Agricola, Manja Burggraf, Anne Hess, Wolfgang Ballensiefen, Wiebke Loebker, Yoana Nuevo, Anna M. G. Pasmooij, Peter G. M. Mol

Summary: Important discoveries in academic drug development hold promise for innovative treatments, but academic researchers face challenges in the drug development process and regulatory barriers. European regulators provide support services, but many academic researchers lack awareness of these tools and face challenges in regulatory knowledge. Improved collaboration and communication are needed to address these issues.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands

Esther de Vries, Elisabeth Bakker, Taco B. M. Monster, Petra Denig, Peter G. M. Mol

Summary: This study aimed to assess the effect of content elements on healthcare professionals' preferences and responses towards DHPCs. The results showed that increased frequency and seriousness of the safety issue were associated with higher perceived importance and a preference for immediate communication. Periodic communication was preferred for less frequent or serious safety issues.

DRUG SAFETY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study

Sonia Roldan Munoz, Douwe Postmus, Sieta T. de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans Hillege, Peter G. M. Mol

Summary: This study explores the differences in the communication of safety issues related to SGLT2 inhibitors among medicines regulatory agencies. The study finds that regulators' opinions on the need to communicate safety issues are influenced by their level of concern. Furthermore, the characteristics of the safety issue, demographic and professional characteristics of the regulators, and their attitudes also influence their level of concern.

DRUG SAFETY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.